• Have fully understood the study and voluntarily signed the informed consent;

• Age 18-75 years old, gender is not limited;

• Histologically confirmed Stage III initial unresectable squamous or non-squamous non-small cell lung cancer (AJCC Stage 8th edition)

• \- Unresectable stage III NSCLC mainly refers to imaging or lymph node pathological evidence: Multiple metastases of ipsilateral mediastinal lymph nodes fused into masses or multisite metastases (IIIA: T1-2N2 or IIIB: T3-4N2); metastases to the contralateral hilar, mediastinal lymph nodes, or to the same, contralateral scalene, or supraclavicular lymph nodes (IIIB: T1-2N3, IIIC: T3-4N3); lesion invasion of important organs (including diaphragm, mediastinum, great blood vessels, trachea, recurrent laryngeal nerve, esophagus, or satellite nodules in different pulmonary lobes on the same side of the primary tumor, resulting in clinician determination that R0 resection could not be performed) (IIIA: T4N0-1); Determination of o N2/N3 lymph node involvement: PET-CT was used to confirm lymph node status. In cases where PET-CT is insufficient to determine lymph node staging (for example, lymph node diameter \<2cm), pathologic confirmation (EBUS/EUS/ thoracoscopic/mediastinoscopy or fine needle aspiration biopsy) is performed by the investigator to select appropriate lymph nodes to determine the staging.

• Clinical evaluation of unresectable Stage III NSCLC: Other clinicians determine that R0 resection is not feasible or that a total lung resection is required to achieve R0 resection.

• At least 1 measurable lesion as defined by RECIST v1.1;

• ECOG score 0-1;

• Eligible for platinum-containing double-drug chemotherapy.

• Good organ function;

• • Patients have not received blood transfusion or growth factor support therapy ≤ 14 days prior to sample collection during the screening period and: Absolute neutral cell count (ANC) ≥1.5 x 109/L

⁃ Platelet ≥100 x 109/L

⁃ Hemoglobin ≥90 g/L

‣ • Calculated creatinine clearance (CrCl) (Cockcroft-Gault formula)

⁃ Patients scheduled to receive cisplatin: creatinine clearance ≥ 60 mL/min

⁃ Patients scheduled to receive carboplatin: creatinine clearance ≥ 45 mL/min

• Serum total bilirubin ≤1.5 × upper limit of normal (ULN) (patients with Gilbert\'s syndrome must have total bilirubin \< 3 × ULN)

∙ AST and ALT≤ 2.5 x ULN

∙ Patients who did not receive anticoagulant therapy: International standardized ratio or activated partial thromboplastin time ≤ 1.5 × ULN

∙ Albumin ≥25 g/L (2.5 g/dL).

• Willing and able to comply with study plan visits, treatment plans, laboratory tests and other study procedures;

• The total amount of lung function, as assessed by the surgeon, is sufficient to withstand the proposed pneumonectomy;

⁃ Women of childbearing age must take a serum pregnancy test within 3 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose of the study drug